ClinicalTrials.gg
Status unknownNCT03269162Updated Sep 14, 2017

Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

A Phase 3 interventional study of Jinfukang Koufuye and Docetaxel in NSCLC, sponsored by lihegen. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by lihegen · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Sep 2016, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Objective: To study the effect of Jinfukang Koufuye combined with chemotherapy on preventing relapse and metastasis of early postoperative NSCLC patients. Method: In this multicenter、prospective、randomized controlled clinical trial, 144 NSCLC patients with complete resection、stage Ib-IIb were randomly divided into Jinfukang Koufuye combined with chemotherapy group (treatment group, N=72) and chemotherapy only group (controlled group, N=72). Peripheral blood CTCs and immune cells were detect on five different time points: after operation、4 chemotherapy cycles were over、12 months after operation、18 months after operation、and 24 months after operation. To evaluate the effect of Jinfukang Koufuye combined with chemotherapy on the level of peripheral blood CTCs、DFS、immune function、quality of life of postoperative patients; and decreasing the side effect of chemotherapy.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

This is the only study on the registry with lihegen as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathology-confirmed diagnosis of primary NSCLC with complete resection, and stage IB-IIB
  2. Accept chemotherapy for the first time 6 weeks after operation
  3. Age of 18-75 years old
  4. -PS≤2
  5. N>1.5×109/L、> 100 × 109/L、>100g/dL、Liver and kidney function is normal or elevated ≤ 1.5 times
  6. Voluntary participation in the prospective study with signed

Exclusion criteria

Exclusion Criteria:

  1. No pathology-confirmed diagnosis patients
  2. Patients with overall survival time\<6 months
  3. Patients with Serious diseases like heart、liver、kidney and hematopoietic system at the same time
  4. Pregnant or breast feeding patients
  5. Patients with uncontrollable mentally disease
  6. Patients with diabetes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Jinfukang + Chemotherapy Group

    Drug: Jinfukang Koufuye · Drug: Docetaxel · Drug: Pemetrexed · Drug: Cisplatin

  • Placebo comparator
    Chemotherapy Group

    Drug: Docetaxel · Drug: Pemetrexed · Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-free survival Rate

    From the very beginning of the randomization to the end point when disease relapse or death because of any reason

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2016 (actual). Primary completion is estimated for Sep 2019, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 31, 2017
StartActual
Sep 30, 2016
Primary completionEst.
Sep 30, 2019
CompletionEst.
Sep 30, 2019
Last update
Sep 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03269162
Lead sponsor
lihegen
Responsible party
lihegen (Director of Oncology Department Longhua Hospital, Shanghai University of Traditional Chinese Medicine) — Sponsor-investigator
First posted
Aug 31, 2017
Start date
Sep 30, 2016
Primary completion
Sep 30, 2019 (estimated)
Completion
Sep 30, 2019 (estimated)
Last update
Sep 14, 2017

Study contacts

Hegen Li
principal investigator · Longhua Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jinfukang

Start the discussion